Germany Attention Deficit Hyperactivity Disorder Therapeutic Market Report 2022 to 2030

Germany ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Germany's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $1.08 Bn in 2022 to $1.68 Bn in 2030 with a CAGR of 5.7% for the year 2022-30. The major market drivers include rising awareness of the disorder and the increasing supply of ADHD drugs which include both stimulants and non-stimulants. The Germany ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major competitors in the market are Adragos Pharma, Hermes Arzneimittel, and Shire.

ID: IN10DEPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Parul Choudhary

Buy Now

Germany Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Germany Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $1.08 Bn in 2022 and is projected to reach $1.68 Bn in 2030, exhibiting a CAGR of 5.7% during the forecast period. In Germany, present health spending in 2022 was funded by transfers and subsidies from the government. This represents a $17.36 Bn (31.5%) rise over 2021, according to the Federal Statistical Office (Destatis). As a consequence, 15.7% of the current health expenditure of $459.80 Bn came from government transfers and subsidies, an increase of 3.0 % in age points from the previous year. Karl Lauterbach, Germany's Minister of Health, intends to increase regular insurer contributions and raid health insurance reserves in order to close a health insurance shortfall of at least $18.10 Bn in the upcoming fiscal year. Contribution increases from blue-collar and white-collar workers are anticipated to generate $5.32 Bn in order to close the financial gap in the health insurance funds.

One of the most prevalent mental disorders in childhood and adolescence is attention-deficit hyperactivity disorder (ADHD), which has the three central symptoms of inattentiveness, hyperactivity (motor unrest), and impulsivity. Over the past few decades, the prevalence of ADHD has stayed largely stable, with an estimated 5% prevalence worldwide. In Germany, ADHD has been formally diagnosed in 4.4% of children and teenagers. Due to the growing external demands put on students in school, ADHD is frequently diagnosed in children of primary school age as symptoms become more pronounced and cause greater impairment.

The prescriber must make sure the patient has a verified diagnosis of ADHD before starting treatment. For the diagnosis of ADHD, current clinical recommendations advise a thorough clinical interview that includes structured and thorough assessments. Additionally, in Germany, statutory health insurance providers do not typically pay for stimulants like methylphenidate (MPH) and lisdexamfetamine (LDX) unless stringent and thorough diagnostic requirements have been met. Although pharmacological therapy is not prohibited for pre-schoolers, guidelines stress that psychosocial interventions should come first.

germany attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

In Germany, there has been a rise in awareness of ADHD, particularly among parents and caretakers. As a result, the disease is being diagnosed and treated earlier, which is increasing the demand for ADHD therapeutics in Germany.

The Germany ADHD therapeutics market is expanding as a result of the expansion in the supply of ADHD medications in Germany. In Germany, a variety of medications, including stimulants and non-stimulants, can be prescribed to treat ADHD.

In Germany, therapeutics for ADHD have seen substantial technological advancements. For the treatment of ADHD, novel drug delivery methods like transdermal patches are being developed. This is fuelling the Germany ADHD therapeutics market's expansion.

Market Restraints

Germany has strict regulatory standards for the approval of novel ADHD medications and treatments. For new companies attempting to enter the market, this may mean longer approval times and higher costs.

While ADHD drugs can be helpful, they can also have unwanted effects like appetite loss, insomnia, and irritability. Patients may become less compliant and show a predilection for alternative treatments as a result.

Competitive Landscape

Key Players

InfectoPharm (DEU)-
Alnylam (DEU)
EUSA Pharma (DEU)
Adragos Pharma (DEU)
Hermes Arzneimittel (DEU)
Shire
Elli Lilly
Novartis
GSK
Mallinckrodt
Hiramitsu
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), also known as BfArM, is the federal organization in charge of approving, monitoring and evaluating drugs and medical equipment in Germany. The BfArM is also in charge of keeping an eye on the efficacy and safety of medicines and medical equipment already sold in Germany. The BfArM's primary duties include the registration of pharmaceuticals as well as the marketing authorization of those goods. Medicinal goods are substances that are employed in the treatment of illnesses, the easing of complaints, or the prevention of such illnesses or complaints. No matter if a medicinal product is given to people or animals, this definition still holds true. The authorization of finished medicinal products on the basis of the Medicinal Products Act ("Arzneimittelgesetz", AMG) is one of the primary tasks of the BfArM. The health benefit, or efficacy, safety, and pharmaceutical quality of the medicinal products, are examined during these licensing processes. Furthermore, the BfArM performs crucial duties in association with drug licensing on a European level, greatly aiding in the reduction of risks to public health.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.